newratings.com  Apr 7  Comment 
Novartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year and above with chronic ITP Novartis International AG / Novartis receives EU approval for Revolade® as first-in-class therapy for children aged 1...
newratings.com  Apr 1  Comment 
WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals Inc. (RIGL) said that it has completed enrollment for both studies in the FIT Phase 3 clinical program of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, in immune thromboycytopenic...
Benzinga  Jan 28  Comment 
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today announced that the first of two Phase 3 clinical studies of fostamatinib in immune thrombocytopenic purpura (ITP) completed patient enrollment this month. The results from this first study are...
Forbes  Dec 25  Comment 
Every year New York University provides lucky New Yorkers with an early holiday present, and 2015 was no exception. NYU’s ITP Winter Show is the work of more than 100 student projects.
newratings.com  Sep 8  Comment 
WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals, Inc. (RIGL) Tuesday said the U.S. Food and Drug Administration has granted Orphan Drug designation to Fostamatinib, Rigel's oral spleen tyrosine kinase or SYK inhibitor which is currently in Phase...
The Economic Times  Sep 3  Comment 
Investors and promoters of small startups are not happy with the reworked institutional trading platform guidelines issued by market regulator Sebi.
newratings.com  Aug 24  Comment 
BASEL (dpa-AFX) - Ligand Pharmaceuticals Inc (LGND) on Monday said the U.S. Food and Drug Administration has approved an expanded use for Promacta (eltrombopag), a product of Novartis (NVS), to include children 1 year of age and older with chronic...

You may also be interested in articles related to Intertape Polymer Group (ITP):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki